Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.12.19
Views: 256
Rating:

Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland

Prof Adrian Ochsenbein speaks to ecancer at the 2019 ASH meeting in Orlando about a phase 1 study looking at the use of the anti-CD70 ADCC-optimised monoclonal antibody cusatuzumab in attacking acute myeloid leukaemia stem cells in humans.

He explains that the study was dose escalated with 12 patients and that a response rate of 100% was seen.

Prof Ochsenbein explains that the next steps are to await results from the expansion of an additional 26 patients which will hopefully hold more insights about potential biomarkers.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation